STAT3 and lymphoma: In particular, antitumor activity of an ASO inhibitor of STAT3 (i.e., AZD9150) was observed in two phase 1 studies in patients with highly treatment‐refractory lymphomas and non‐small cell lung cancer (Hong et al., 2015; Reilley et al., 2018).